Proteins

## BET-IN-19

Cat. No.: HY-125236 CAS No.: 1643947-30-1 Molecular Formula:  $C_{19}H_{19}N_5O$ Molecular Weight: 333.39

Target: **Epigenetic Reader Domain** 

Pathway: **Epigenetics** 

Storage: Powder -20°C 3 years

> In solvent -80°C 6 months

> > -20°C 1 month

**Product** Data Sheet

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (299.95 mM; Need ultrasonic)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9995 mL	14.9974 mL	29.9949 mL
	5 mM	0.5999 mL	2.9995 mL	5.9990 mL
	10 mM	0.2999 mL	1.4997 mL	2.9995 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.50 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description

BET-IN-19 (Compound 146) is a BET inhibitor. BET-IN-19 inhibits hlL-6 mRNA transcription (IC<sub>50</sub> ≤ 0.3 uM), and c-myc activity in human AML MV4-11 cell (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC $_{50} \le 0.3$  uM) \( \text{MBET-IN-19} inhibits tetra-a  $(IC_{50} \le 0.3 \text{ uM})^{[1]}$ .

### **REFERENCES**

1]. Bryan Cordell DUFFY, et al.	Novel bicyclic bromodom	ain inhibitors. Patent. WO2015002	134 MZ.	
			nedical applications. For research use only.	
	Tel: 609-228-6898 Address	Fax: 609-228-5909 s: 1 Deer Park Dr, Suite Q, Monm	E-mail: tech@MedChemExpress.com outh Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com